Generic Name and Formulations:
Methocarbamol 750mg; tabs.
- Romiplostim May Not Increase Acute Myeloid Leukemia Risk
- Ceritinib Improves Survival Benefit and Response Rate Compared to Chemotherapy in Patients With NSCLC
- Adding Everolimus to R-CHOP Feasible for Diffuse Large B-cell Lymphoma
- Muscle Spasm Treatments
- Esophageal and Esophagogastric Junction Cancer Treatment Regimens
- Gastric Cancer Treatment Regimens
Indications for ROBAXIN-750:
Painful musculoskeletal conditions.
≥16yrs: initially 1.5g 4 times daily for 2–3 days; if severe, may give up to 8g/day. Maintenance: 750mg every 4 hours or 1.5g 3 times daily.
<16yrs: not recommended.
Pregnancy (Cat.C). Nursing mothers.
Alcohol and other CNS depressants potentiated. May antagonize pyridostigmine.
Muscle relaxant (central).
Drowsiness, dizziness, GI upset, blurred vision, headache.
Tabs 500mg—100; 750mg—100, 500
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC